NEW YORK — German molecular diagnostics firm Epigenomics on Thursday said its second quarter revenues declined 76 percent year over year, primarily due to the effects of the COVID-19 pandemic.
For the three-month period ended June 30, Epigenomics revenues fell to €83,000 ($98,204) from €348,000 in the year-ago quarter. The company attributed the decline to the almost complete loss of revenues in its US business because of COVID-19.
The company's Q2 product revenues declined 78 percent to €73,000 from €339,000 a year ago.